Core Viewpoint - Federal Pharmaceutical (03933) shows a stock increase of over 4%, currently at 16.96 HKD with a trading volume of 96.8 million HKD, indicating positive market sentiment despite mixed financial performance [1] Financial Performance - Revenue for the first half of 2025 is projected to grow by 5% year-on-year, while net profit is expected to increase by 27% [1] - Excluding business development income, there is a significant decline of 50% in net profit [1] - Sales of intermediates and active pharmaceutical ingredients decreased by 23% and 27% respectively, primarily due to falling product prices [1] Product Development - The GLP-1/GIP/GCG tri-target receptor agonist UBT251 completed patient recruitment for obesity phase II trials in April and diabetes trials in May, with ongoing recruitment for metabolic-associated fatty liver disease and chronic kidney disease phase II trials [1] - Management aims to submit a clinical trial application for the innovative drug UBT48128 by the first half of 2026 [1] - New production capacity for high-barrier active pharmaceutical ingredients and Inner Mongolia's active pharmaceutical ingredients is set to commence in October this year [1]
联邦制药涨超4% 上半年高栏原料药新产能及内蒙古原料药产能将于10月投产